Glory Health Industry Limited (2329.HK)
HKD 0.04
(21.21%)
HKD 0.04
(21.21%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -145.85 Million CNY | 52.95% |
| 2022 | -325.93 Million CNY | -156.05% |
| 2021 | 581.54 Million CNY | 81.85% |
| 2020 | 1.09 Billion CNY | -76.34% |
| 2019 | 1.35 Billion CNY | -30.94% |
| 2018 | 1.95 Billion CNY | -26.02% |
| 2017 | 2.64 Billion CNY | 3.32% |
| 2016 | 2.56 Billion CNY | 21.89% |
| 2015 | 2.1 Billion CNY | 6.54% |
| 2014 | 1.97 Billion CNY | -40.29% |
| 2013 | 3.3 Billion CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q4 | -357.63 Million CNY | -610.24% |
| 2023 Q2 | -50.35 Million CNY | -141.32% |
| 2023 FY | - CNY | 52.95% |
| 2022 Q2 | -447.8 Million CNY | -120.05% |
| 2022 Q4 | 121.87 Million CNY | 127.22% |
| 2022 FY | - CNY | -156.05% |
| 2021 Q2 | 785.04 Million CNY | 489.93% |
| 2021 FY | - CNY | 81.85% |
| 2021 Q4 | -203.5 Million CNY | -125.92% |
| 2020 Q4 | -201.33 Million CNY | -138.63% |
| 2020 FY | - CNY | -76.34% |
| 2020 Q2 | 521.12 Million CNY | -22.35% |
| 2019 Q2 | 680.41 Million CNY | -53.06% |
| 2019 Q4 | 671.07 Million CNY | -1.37% |
| 2019 FY | - CNY | -30.94% |
| 2018 Q4 | 1.44 Billion CNY | 185.62% |
| 2018 FY | - CNY | -26.02% |
| 2018 Q2 | 507.45 Million CNY | -73.51% |
| 2017 Q2 | 729.12 Million CNY | -44.69% |
| 2017 FY | - CNY | 3.32% |
| 2017 Q4 | 1.91 Billion CNY | 162.76% |
| 2016 FY | - CNY | 21.89% |
| 2016 Q2 | 1.24 Billion CNY | 18.81% |
| 2016 Q4 | 1.31 Billion CNY | 6.15% |
| 2015 Q4 | 1.04 Billion CNY | -0.94% |
| 2015 Q2 | 1.05 Billion CNY | -15.51% |
| 2015 FY | - CNY | 6.54% |
| 2014 Q4 | 1.24 Billion CNY | 72.85% |
| 2014 Q2 | 722.49 Million CNY | -40.0% |
| 2014 FY | - CNY | -40.29% |
| 2013 Q4 | 1.2 Billion CNY | -42.59% |
| 2013 FY | - CNY | 0.0% |
| 2013 Q2 | 2.09 Billion CNY | 134.6% |
| 2012 Q4 | 894.07 Million CNY | 0.0% |